Literature DB >> 16279954

Hairpin ribozymes in combination with siRNAs against highly conserved hepatitis C virus sequence inhibit RNA replication and protein translation from hepatitis C virus subgenomic replicons.

Dominik Jarczak1, Mortimer Korf, Carmela Beger, Michael P Manns, Martin Krüger.   

Abstract

Chronic hepatitis C virus (HCV) infection is a clinically important liver disease with limited therapeutic options in a significant proportion of patients. Therefore, novel efficient therapeutic agents are needed. Because the 5'- and 3'-untranslated regions (UTRs) of HCV are highly conserved and functionally important for HCV replication, they are attractive targets for RNA-cleaving ribozymes or small interfering RNAs (siRNAs). In this study hairpin ribozymes (Rz) targeting HCV 5'- and 3'-UTR sequences were expressed from a retroviral vector transcript under control of two different RNA polIII promoters (tRNA(Val), U6). Ribozymes were evaluated in monocistronic, subgenomic I389/hyg-ubi/NS3-3'/5.1 HCV replicon cells as single agents or in combination with siRNAs against HCV 5'- or 3'-UTR recently demonstrated to inhibit HCV replicons. Additionally, ribozyme constructs were generated with the 3'-terminus of the ribozyme flanked by constitutive transport element (CTE) sequences, an RNA motif that has previously been shown to enhance cleavage activity of hammerhead ribozymes. In our study, tRNA(Val) as well as U6 promoter-driven Rzs markedly reduced HCV replicon RNA expression and HCV internal ribosome entry site (IRES)-mediated HCV NS5B protein translation from monocistronic subgenomic replicons. However, attachment of CTE sequences to the 3'-terminus did not significantly enhance activity of Rzs tested in this study. Interestingly, we detected additive HCV inhibitory effects for combinations of tRNA(Val)-driven Rzs and U6-derived siRNAs both directed against highly conserved 5'- and 3'-UTR sequence, suggesting that a dual strategy of ribozymes and siRNAs might become a powerful molecular tool to specifically silence HCV RNA replication.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16279954     DOI: 10.1111/j.1742-4658.2005.04986.x

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  14 in total

1.  Trans-splicing group I intron targeting hepatitis C virus IRES mediates cell death upon viral infection in Huh7.5 cells.

Authors:  Pruksa Nawtaisong; Mark E Fraser; James R Carter; Malcolm J Fraser
Journal:  Virology       Date:  2015-04-07       Impact factor: 3.616

2.  All for one, one for all: new combinatorial RNAi therapies combat hepatitis C virus evolution.

Authors:  Dirk Grimm
Journal:  Mol Ther       Date:  2012-09       Impact factor: 11.454

3.  Potent Intracellular Knock-Down of Influenza A Virus M2 Gene Transcript by DNAzymes Considerably Reduces Viral Replication in Host Cells.

Authors:  Binod Kumar; Roopali Rajput; Dibya Ranjan Pati; Madhu Khanna
Journal:  Mol Biotechnol       Date:  2015-09       Impact factor: 2.695

4.  Small interfering RNA targeted to hepatitis C virus 5' nontranslated region exerts potent antiviral effect.

Authors:  Tatsuo Kanda; Robert Steele; Ranjit Ray; Ratna B Ray
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

5.  Discovery and characterization of substituted diphenyl heterocyclic compounds as potent and selective inhibitors of hepatitis C virus replication.

Authors:  Peiyong Huang; Dane A Goff; Qi Huang; Anthony Martinez; Xiang Xu; Scott Crowder; Sarkiz D Issakani; Emily Anderson; Ning Sheng; Philip Achacoso; Ann Yen; Todd Kinsella; Ihab S Darwish; Rao Kolluri; Hui Hong; Kunbin Qu; Emily Stauffer; Eileen Goldstein; Rajinder Singh; Donald G Payan; H Henry Lu
Journal:  Antimicrob Agents Chemother       Date:  2008-01-28       Impact factor: 5.191

Review 6.  Hepatitis C virus translation inhibitors targeting the internal ribosomal entry site.

Authors:  Sergey M Dibrov; Jerod Parsons; Maia Carnevali; Shu Zhou; Kevin D Rynearson; Kejia Ding; Emily Garcia Sega; Nicholas D Brunn; Mark A Boerneke; Maria P Castaldi; Thomas Hermann
Journal:  J Med Chem       Date:  2013-11-05       Impact factor: 7.446

Review 7.  Prospects for nucleic acid-based therapeutics against hepatitis C virus.

Authors:  Chang Ho Lee; Ji Hyun Kim; Seong-Wook Lee
Journal:  World J Gastroenterol       Date:  2013-12-21       Impact factor: 5.742

Review 8.  siRNAs: potential therapeutic agents against hepatitis C virus.

Authors:  Usman A Ashfaq; Muhammad Z Yousaf; Maida Aslam; Rahat Ejaz; Shah Jahan; Obaid Ullah
Journal:  Virol J       Date:  2011-06-06       Impact factor: 4.099

9.  AAV-mediated in vivo knockdown of luciferase using combinatorial RNAi and U1i.

Authors:  A Koornneef; R van Logtenstein; E Timmermans; L Pisas; B Blits; X Abad; P Fortes; H Petry; P Konstantinova; T Ritsema
Journal:  Gene Ther       Date:  2011-04-07       Impact factor: 5.250

10.  The anti-genomic (negative) strand of Hepatitis C Virus is not targetable by shRNA.

Authors:  Leszek Lisowski; Menashe Elazar; Kirk Chu; Jeffrey S Glenn; Mark A Kay
Journal:  Nucleic Acids Res       Date:  2013-02-08       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.